117 related articles for article (PubMed ID: 28071184)
1. Letter from the Editor.
Pedersen AE
Immunopharmacol Immunotoxicol; 2017 Feb; 39(1):1. PubMed ID: 28071184
[No Abstract] [Full Text] [Related]
2. Letter from the Editor.
Hum Vaccin Immunother; 2016; 12(1):1. PubMed ID: 26836324
[No Abstract] [Full Text] [Related]
3. Letter from the editor.
Ellis R; Riedmann EM
Hum Vaccin Immunother; 2014; 10(1):1-2. PubMed ID: 24832715
[No Abstract] [Full Text] [Related]
4. [Clinical immunology 2007].
Behrens GM; Schmidt RE
Dtsch Med Wochenschr; 2007 Jun; 132(25-26):1404-6. PubMed ID: 17570090
[No Abstract] [Full Text] [Related]
5. Letter from the editor.
Ellis R; Weiss A
Hum Vaccin Immunother; 2015; 11(2):303. PubMed ID: 25826191
[No Abstract] [Full Text] [Related]
6. [Managing patients with therapeutic antibodies in odontostomatology].
Demoersman J; Soueidan A; Corre P; Pers JO
Rev Stomatol Chir Maxillofac Chir Orale; 2014 Jun; 115(3):152-63. PubMed ID: 24797731
[TBL] [Abstract][Full Text] [Related]
7. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
Morse MA
Curr Opin Mol Ther; 2005 Dec; 7(6):588-97. PubMed ID: 16370382
[TBL] [Abstract][Full Text] [Related]
8. Letter from the Editor.
Ellis R; Weiss A
Hum Vaccin Immunother; 2015; 11(6):1297. PubMed ID: 26086583
[No Abstract] [Full Text] [Related]
9. Targeting cancer therapy.
Begent RH
Br J Cancer; 1999 Jul; 80 Suppl 1():104-9. PubMed ID: 10466768
[No Abstract] [Full Text] [Related]
10. Letter from the editor.
Ellis R; Riedmann EM
Hum Vaccin Immunother; 2013 Feb; 9(2):227. PubMed ID: 23449313
[No Abstract] [Full Text] [Related]
11. Hyperimmune goat serum (Aimspro): hope or hype?
Sutton I; Kermode AG
J Clin Neurosci; 2006 Dec; 13(10):1037-8. PubMed ID: 17049444
[No Abstract] [Full Text] [Related]
12. Letter from the editor.
Ellis R; Riedmann EM
Hum Vaccin Immunother; 2014; 10(7):1771-2. PubMed ID: 25424780
[No Abstract] [Full Text] [Related]
13. Promising early results for immunotherapy-antiangiogenesis combination.
Garber K
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421345
[No Abstract] [Full Text] [Related]
14. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing.
Ryan JM; Grundman M
J Alzheimers Dis; 2009; 17(2):243. PubMed ID: 19502708
[No Abstract] [Full Text] [Related]
15. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
17. Immune intervention with anti-CD3 in diabetes.
Harlan DM; von Herrath M
Nat Med; 2005 Jul; 11(7):716-8. PubMed ID: 16015359
[No Abstract] [Full Text] [Related]
18. The little antibody that could.
Gorman C
Time; 2002 Jun; 159(23):69. PubMed ID: 12066498
[No Abstract] [Full Text] [Related]
19. Immune therapy for ovarian cancer: promise and pitfalls.
Thibodeaux SR; Curiel TJ
Int Rev Immunol; 2011; 30(2-3):102-19. PubMed ID: 21557637
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy shows promise in Phase III neuroblastoma trial.
Nat Rev Drug Discov; 2009 Aug; 8(8):604. PubMed ID: 19644467
[No Abstract] [Full Text] [Related]
[Next] [New Search]
